137 related articles for article (PubMed ID: 11843248)
1. Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer.
Meyer T; Nelstrop AE; Mahmoudi M; Rustin GJ
Ann Oncol; 2001 Dec; 12(12):1705-9. PubMed ID: 11843248
[TBL] [Abstract][Full Text] [Related]
2. Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Pitakkarnkul S; Tangjitgamol S; Srijaipracharoen S; Manusirivithaya S; Pataradool K; Prutthiphongsit W; Khunnarong J; Thavaramara T
Asian Pac J Cancer Prev; 2013; 14(4):2421-7. PubMed ID: 23725151
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
Komiyama S; Kato K; Inokuchi Y; Takano H; Matsumoto T; Hongo A; Asai-Sato M; Arakawa A; Kamiura S; Tabata T; Takeshima N; Sugiyama T
Int J Clin Oncol; 2019 Jan; 24(1):103-114. PubMed ID: 30030657
[TBL] [Abstract][Full Text] [Related]
4. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
5. A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum-based chemotherapy: results of a Phase II study.
Benedetti Panici P; Greggi S; Amoroso M; Scambia G; Battaglia FA; Gebbia V; Salerno G; Paratore MP; Mancuso S
Int J Gynecol Cancer; 2001; 11(6):438-44. PubMed ID: 11906546
[TBL] [Abstract][Full Text] [Related]
6. Local radiation therapy for localized relapsed or refractory ovarian cancer patients with or without symptoms after chemotherapy.
Fujiwara K; Suzuki S; Yoden E; Ishikawa H; Imajo Y; Kohno I
Int J Gynecol Cancer; 2002; 12(3):250-6. PubMed ID: 12060445
[TBL] [Abstract][Full Text] [Related]
7. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.
Boisen MM; Lesnock JL; Richard SD; Beriwal S; Kelley JL; Zorn KK; Edwards RP
Int J Gynecol Cancer; 2016 May; 26(4):626-31. PubMed ID: 27051048
[TBL] [Abstract][Full Text] [Related]
8. Intra-peritoneal cisplatin combined with intravenous paclitaxel in optimally debulked stage 3 ovarian cancer patients: an Izmir Oncology Group study.
Unal OU; Yilmaz AU; Yavuzsen T; Akman T; Ellidokuz H
Asian Pac J Cancer Prev; 2014; 15(15):6165-9. PubMed ID: 25124592
[TBL] [Abstract][Full Text] [Related]
9. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.
Colombo PE; Labaki M; Fabbro M; Bertrand M; Mourregot A; Gutowski M; Saint-Aubert B; Quenet F; Rouanet P; Mollevi C
Gynecol Oncol; 2014 Nov; 135(2):223-30. PubMed ID: 25220627
[TBL] [Abstract][Full Text] [Related]
10. Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study.
Sayal K; Gounaris I; Basu B; Freeman S; Moyle P; Hosking K; Iddawela M; Jimenez-Linan M; Abraham J; Brenton J; Hatcher H; Earl H; Parkinson C
Int J Gynecol Cancer; 2015 Jul; 25(6):977-84. PubMed ID: 25962114
[TBL] [Abstract][Full Text] [Related]
11. Weekly cisplatin with oral etoposide: a well-tolerated and highly effective regimen in relapsed ovarian cancer.
Verborg WA; Campbell LR; Highley MS; Rankin EM
Int J Gynecol Cancer; 2008; 18(2):228-34. PubMed ID: 17511798
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant platinum-based chemotherapy in patients with epithelial ovarian cancer: prognostic factors and final outcome.
Grivas A; Lianos E; Internos I; Papaxoinis G; Tselepatiotis E; Ziras N; Athanasiou AE
J BUON; 2010; 15(4):647-51. PubMed ID: 21229624
[TBL] [Abstract][Full Text] [Related]
13. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer.
Sufliarsky J; Chovanec J; Svetlovska D; Minarik T; Packan T; Kroslakova D; Lalabova R; Helpianska L; Horvathova D; Sevcik L; Spacek J; Laluha A; Tkacova V; Malec V; Rakicka G; Magdin D; Jancokova I; Dorr A; Stresko M; Habetinek V; Koza I
Neoplasma; 2009; 56(4):291-7. PubMed ID: 19473054
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy.
de Wit R; van der Burg ME; van den Gaast A; Logmans A; Stoter G; Verweij J
Ann Oncol; 1994 Sep; 5(7):656-7. PubMed ID: 7993845
[TBL] [Abstract][Full Text] [Related]
16. First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in Stage IIIc ovarian epithelial cancer.
Zylberberg B; Dormont D; Madelenat P; Daraï E
Eur J Gynaecol Oncol; 2004; 25(3):327-32. PubMed ID: 15171311
[TBL] [Abstract][Full Text] [Related]
17. Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer.
Li LY; Kim SW; Nam EJ; Lee J; Kim S; Kim YT
Int J Gynecol Cancer; 2019 Feb; 29(2):334-340. PubMed ID: 30718314
[TBL] [Abstract][Full Text] [Related]
18. Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma.
Dunder I; Berker B; Atabekoglu C; Bilgin T
Eur J Gynaecol Oncol; 2005; 26(1):79-82. PubMed ID: 15755007
[TBL] [Abstract][Full Text] [Related]
19. Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer.
van der Burg ME; de Wit R; van Putten WL; Logmans A; Kruit WH; Stoter G; Verweij J
Br J Cancer; 2002 Jan; 86(1):19-25. PubMed ID: 11857006
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
Sánchez-Muñoz A; Mendiola C; Pérez-Ruiz E; Rodríguez-Sánchez CA; Jurado JM; Alonso-Carrión L; Ghanem I; de Velasco G; Quero-Blanco C; Alba E
Oncology; 2010; 79(1-2):98-104. PubMed ID: 21079407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
